|

[18F]F-AraG Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: VisAcT

Pipeline

Phase 2: 2

Top Sponsors

  • CellSight Technologies, Inc.2

Indications

  • Cancer2
  • Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit1
  • Advanced Non-Small Cell Lung Cancer1
  • Lung Cancer1

Stanford, California1 trial

A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

Stanford University

Phase 2

Iowa City, Iowa1 trial

Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

University of Iowa Hospitals and Clinics

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.